Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
1.
Int J Drug Policy ; 110: 103873, 2022 Oct 14.
Article in English | MEDLINE | ID: covidwho-2076059

ABSTRACT

OBJECTIVE: To identify missed opportunities for healthcare providers to discuss HIV pre-exposure prophylaxis (PrEP) with people who inject drugs (PWID). METHODS: Participants were 395 HIV-negative PWID recruited for the 2018 National HIV Behavioral Surveillance survey in San Francisco, California via respondent-driven sampling. Adjusted logistic regression tested whether discussing PrEP with a provider in the last year was associated with sociodemographic characteristics, structural factors, and accessing HIV/STI and substance use treatment services. RESULTS: Most PWID (86.3%) reported seeing a healthcare provider, but only 15.0% of these reported discussing PrEP with a healthcare provider. PWID who were sexual minority men had greater odds of having a discussion about PrEP with a healthcare provider than PWID who were heterosexual men (aOR=3.42, 95% CI=1.21-9.73) or heterosexual women (aOR=3.69, 95% CI=1.08-12.62). Additionally, factors associated with discussing PrEP included: being tested for HIV (aOR=4.29, 95% CI=1.21-15.29), having a healthcare provider recommend HIV testing (aOR=2.95, 95% CI=1.23-7.06), and receiving free condoms from a prevention program (aOR=5.45, 95% CI=1.78-16.65). CONCLUSIONS: In the face of low PrEP uptake, continuing HIV transmission, and many missed opportunities to discussed PrEP (e.g., PWID who are women, substance use treatment services), these findings from San Francisco indicate that healthcare providers and public health efforts need to systematically offer PrEP to PWID. Additional research may clarify missed opportunities in other locations as well as the impact of COVID-19.

2.
PLoS One ; 17(3): e0264929, 2022.
Article in English | MEDLINE | ID: covidwho-1938420

ABSTRACT

BACKGROUND: People experiencing homelessness who live in congregate shelters are at high risk of SARS-CoV2 transmission and severe COVID-19. Current screening and response protocols using rRT-PCR in homeless shelters are expensive, require specialized staff and have delays in returning results and implementing responses. METHODS: We piloted a program to offer frequent, rapid antigen-based tests (BinaxNOW) to residents and staff of congregate-living shelters in San Francisco, California, from January 15th to February 19th, 2021. We used the Reach-Effectiveness-Adoption-Implementation-Maintenance (RE-AIM) framework to evaluate the implementation. RESULTS: Reach: We offered testing at ten of twelve eligible shelters. Shelter residents and staff had variable participation across shelters; approximately half of eligible individuals tested at least once; few tested consistently during the study. Effectiveness: 2.2% of participants tested positive. We identified three outbreaks, but none exceeded 5 cases. All BinaxNOW-positive participants were isolated or left the shelters. Adoption: We offered testing to all eligible participants within weeks of the project's initiation. Implementation: Adaptations made to increase reach and improve consistency were promptly implemented. Maintenance: San Francisco Department of Public Health expanded and maintained testing with minimal support after the end of the pilot. CONCLUSION: Rapid and frequent antigen testing for SARS-CoV2 in homeless shelters is a viable alternative to rRT-PCR testing that can lead to immediate isolation of infectious individuals. Using the RE-AIM framework, we evaluated and adapted interventions to enable the expansion and maintenance of protocols.


Subject(s)
COVID-19 Serological Testing/methods , COVID-19/diagnosis , Ill-Housed Persons/statistics & numerical data , COVID-19/immunology , COVID-19 Testing/methods , California , Disease Outbreaks/prevention & control , Housing , Humans , Immunologic Tests/methods , Mass Screening/methods , Pilot Projects , SARS-CoV-2/immunology , SARS-CoV-2/pathogenicity , San Francisco
3.
Int J STD AIDS ; 33(3): 282-288, 2022 03.
Article in English | MEDLINE | ID: covidwho-1779542

ABSTRACT

BACKGROUND: Afghanistan adopted a "test and treat" strategy for all people living with HIV (PLWH) in 2016. In this study, we presented demographic and clinical characteristics of all people diagnosed between 2013 and 2019 and evaluated progress towards 90-90-90 UNAIDS targets and identified program gaps among PLWH in Afghanistan diagnosed in 2018. METHODS: We used clinical, behavioral, and demographic data from national HIV surveillance for 1394 patients diagnosed from 2013 through 2019. We also tracked 184 patients diagnosed with HIV in 2018 over 15 months to assess their enrollment in care, antiretroviral therapy (ART) initiation, retention on ART, and viral suppression. RESULTS: Of 1394 patients diagnosed from 2013 through 2019, 76.0% were male, 73.7% were older than 24 years, and 33.4% acquired HIV through heterosexual sex. Of the 184 patients diagnosed in 2018, 94.6% were enrolled in care, 88.6% received ART, 84.2% were retained on ART for at least 12 months, and 33.7% received a viral load test. Of those with a viral load test, 74.2% were virally suppressed. Patients who were 35-44 years old (52.0%, p-value .001), acquired HIV through unsafe injection (62.5%, p-value .413), were co-infected with hepatitis C virus (HCV) (60.0%, p-value .449), and with CD4 > 500 at diagnosis (64.7%, p-value .294) were less likely to be virally suppressed 12 months after diagnosis. CONCLUSION: Nearly 95% of people diagnosed with HIV in Afghanistan in 2018 were linked to care and nearly 90% were on ART. Viral testing and viral suppression remain low with notable disparities for middle-aged patients, and possibly for those who injected drugs. Addressing barriers to HIV programs in Afghanistan, particularly for people who inject drugs (PWID), are urgently needed to reach the 90-90-90 global targets. Surveillance data on the number of people with undiagnosed HIV is needed to assess the first 90 target.


Subject(s)
HIV Infections , Adult , Afghanistan/epidemiology , Continuity of Patient Care , HIV Infections/diagnosis , HIV Infections/drug therapy , HIV Infections/epidemiology , Heterosexuality , Humans , Male , Middle Aged , Viral Load
4.
Int J Environ Res Public Health ; 18(6)2021 03 22.
Article in English | MEDLINE | ID: covidwho-1154375

ABSTRACT

OBJECTIVES: We investigated the extent to which Brazilian and Portuguese Men Who Have Sex with Men (MSM) had casual sex partners outside their homes during the period of sheltering in place for the COVID-19 pandemic. METHODS: An online survey was conducted in Brazil and Portugal in April, during the period of social isolation for COVID-19, with a sample of 2361 MSMs. Recruitment was done through meeting apps and Facebook. RESULTS: Most of the sample (53.0%) had casual sex partners during sheltering. Factors that increased the odds of engaging in casual sex in Brazil were having group sex (aOR 2.1, 95% CI 1.3-3.4), living in an urban area (aOR 1.6, 95% CI 1.1-2.2), feeling that sheltering had a high impact on daily life (aOR 3.0, 95% CI 1.1-8.3), having casual instead of steady partners (aOR 2.5, 95% CI 1.8-3.5), and not decreasing the number of partners (aOR 6.5, 95% CI 4.2-10.0). In Portugal, the odds of engaging in casual sex increased with using Facebook to find partners (aOR 4.6, 95% CI 3.0-7.2), not decreasing the number of partners (aOR 3.8, 95% CI 2.9-5.9), usually finding partners in physical venues (pre-COVID-19) (aOR 5.4, 95% CI 3.2-8.9), feeling that the isolation had a high impact on daily life (aOR 3.0, 95% CI 1.3-6.7), and HIV-positive serostatus (aOR 11.7, 95% CI 4.7-29.2). Taking PrEP/Truvada to prevent COVID-19 was reported by 12.7% of MSM. CONCLUSIONS: The pandemic has not stopped most of our MSM sample from finding sexual partners, with high-risk sexual behaviors continuing.


Subject(s)
COVID-19 , HIV Infections , Sexual and Gender Minorities , Brazil , Cross-Sectional Studies , HIV Infections/epidemiology , HIV Infections/prevention & control , Homosexuality, Male , Humans , Male , Pandemics , Portugal , Risk-Taking , SARS-CoV-2 , Sexual Behavior , Sexual Partners , Surveys and Questionnaires
5.
Arch Iran Med ; 23(11): 776-781, 2020 11 01.
Article in English | MEDLINE | ID: covidwho-940549

ABSTRACT

BACKGROUND: Mass screening for the coronavirus disease 2019 (COVID-19) began in Iran on March 23, 2020, with the purpose of improving early detection of patients for their own health and to prevent onward transmission to others. In this study, we evaluated the impact of the change towards mass screening on new cases reported, cases recovered, and deaths due to COVID-19. METHODS: This study analyzed the daily reports on the number of new cases confirmed by polymerase chain reaction (PCR) testing, cases recovered, and deaths due to COVID-19 provided to the Ministry of Health and Medical Education of Iran. Changes in trends on these outcomes were evaluated using interrupted time series analysis. RESULTS: From February 19 to May 6, 2020, a total of 519544 COVID-19 tests were done and 101650 diagnoses were made (case/ test ratio 19.6%). For the same period, 6418 deaths due to COVID-19 were reported (case fatality ratio 6.3%). The number of cases detected increased significantly over the period of scale-up of mass screening (P=0.003), as did the number of recovered cases (P=0.001). The number of deaths due to COVID-19 did not change before versus after mass screening. CONCLUSION: Following the scale-up of mass screening for COVID-19 in Iran, the rate of new cases detected and reported recovered accelerated significantly. Mass screening is likely to have detected many mild and asymptomatic cases that were infectious. Our data support the role that mass screening, coupled with isolation and contract tracing, can have in slowing the COVID-19 epidemic.


Subject(s)
COVID-19/diagnosis , Mass Screening/statistics & numerical data , Adult , COVID-19/mortality , COVID-19/transmission , COVID-19 Nucleic Acid Testing/statistics & numerical data , Female , Humans , Interrupted Time Series Analysis , Iran/epidemiology , Male , Pandemics/prevention & control , SARS-CoV-2
6.
AIDS Behav ; 25(1): 85-92, 2021 Jan.
Article in English | MEDLINE | ID: covidwho-688962

ABSTRACT

This systematic review summarizes the evidence on the earliest patients with COVID-19-HIV co-infection. We searched PubMed, Scopus, Web of Science, Embase, preprint databases, and Google Scholar from December 01, 2019, to June 1, 2020. From an initial 547 publications and 75 reports, 25 studies provided specific information on COVID-19 patients living with HIV. Studies described 252 patients, 80.9% were male, the mean age was 52.7 years, and 98% were on antiretroviral treatment (ART). Co-morbidities in addition to HIV and COVID-19 (multimorbidity) included hypertension (39.3%), obesity or hyperlipidemia (19.3%), chronic obstructive pulmonary disease (18.0%), and diabetes (17.2%). Two-thirds (66.5%) had mild to moderate symptoms, the most common being fever (74.0%) and cough (58.3%). Among patients who died, the majority (90.5%) were over 50 years old, male (85.7%), and had multimorbidity (64.3%). Our findings highlight the importance of identifying co-infections, addressing co-morbidities, and ensuring a secure supply of ART for PLHIV during the COVID-19 pandemic.


Subject(s)
COVID-19/complications , HIV Infections/complications , SARS-CoV-2 , Anti-HIV Agents/therapeutic use , Coinfection , HIV Infections/drug therapy , Humans , Middle Aged , Pandemics
SELECTION OF CITATIONS
SEARCH DETAIL